Edecesertib

Cat. No.: HY-147264

CAS No.: 2408839-73-4

Molecular Formula: $C_{22}H_{22}FN_7O_2$

Molecular Weight: 435.45

Target: IRAK

Pathway: Immunology/Inflammation

Storage: 4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (229.65 mM; Need ultrasonic)

Preparing Stock Solutions	Mass / Solvent / Concentration	1 mg	5 mg	10 mg
	1 mM	2.2965 mL	11.4824 mL	22.9647 mL
	5 mM	0.4593 mL	2.2965 mL	4.5929 mL
	10 mM	0.2296 mL	1.1482 mL	2.2965 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.5 mg/mL (5.74 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 2.5 mg/mL (5.74 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Edecesertib (GS-5718) is a selective, potent, orally active IRAK-4 inhibitor. Edecesertib has anti-inflammatory activity. Edecesertib can be used for rheumatoid arthritis (RA) and lupus erythematosus (LE) research[1][2].

REFERENCES

[1]. Roedder S, et, al. Phase 1 Study Results of GS-5718, an Oral IRAK4-Inhibitor: Pharmacodynamics of Single and Multiple Doses of GS-5718 in Healthy Subjects. 2021 Nov 6.

[2]. WHO Drug Information. International Nonproprietary Names for Pharmaceutical

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA